Gastroenterology
Targeting TudS could be a potential therapeutic approach for treating C. difficile infections.
Each Fusobacterium nucleatum population has unique traits and distribution patterns across body sites and conditions such as colorectal cancer and Crohn’s disease.
Gut microbiota-produced bile acids can be used as therapeutic targets for multiple sclerosis.
At the upcoming 13th edition of the Probiotics, Prebiotics, and New Food Congress in Rome, Professor Emma Allen-Vercoe, PhD from the University of Guelph (Canada), will present groundbreaking research on…
Nutrient competition is the main mechanism of C. difficile inhibition, hinting at the potential for targeted therapies with probiotics instead of traditional FMT.
Researchers have developed new tools to better understand the role of Bifidobacterium breve, revealing its competitive growth strategies and potential for supporting the immune system.
Delayed microbiota maturation in infants with cystic fibrosis could contribute to disease complications, highlighting potential therapeutic targets.
Understanding the complex interactions between exercise, diet and gut health can help to develop approaches to influence the gut microbiota, boost immunity and prevent or manage gastrointestinal diseases.
Phages could be used as a drug delivery system for conditions such as inflammation and obesity.
L-ornithine can be an additional therapy to boost the efficacy of ustekinumab in people with Crohn’s disease.
